Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody
Authors' conclusion
Rapidly progressive interstitial lung disease, anti-Ro52 antibody levels, and age > 57 years are possible predictors of mortality risk in patients with anti-MDA5 dermatomyositis.
Study context
- Population
- Adults with anti-MDA5 DM
- Participants
- 126 adults
- Exposure
- Non-survival vs survival
- Non-survivaln = 32
- Outcome
- Predictors of poor survival
Methodological detailsKaplan-Meier and Cox regression analyses
- Kaplan-Meier and Cox regression analyses
Main finding
As reported in the abstract
Independent prognostic factors for mortality (Kaplan-Meier and Cox multivariate regression)
- Rapidly progressive ILD, anti-Ro52 antibody levels and age > 57 years were important prognostic factors independent of multiple clinical parameters
Observational data: associations, not effects.
Further findings
Cause of death
- Most died from respiratory failure, with pulmonary infection accounting for half
Baseline differences, non-survival vs survival
- Aspartate transaminase, lactate dehydrogenase, ferritin, ESR and anti-Ro52 antibody levels significantly higher, lymphocyte count lower in non-survival
- Non-survival more likely to present with rapidly progressive ILD
- Epstein-Barr virus infection relatively common in both groups
Original publication
Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody. Arthritis Res Ther. Published 24 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →